Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 14/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17694561 | 0.84 | NOTUM (0.78) | NOTUMKDM4EALDH1A1LMNATLR8 | |
| SCHEMBL2610163 | 0.81 | NOTUM (0.75) | NOTUMKDM4EALDH1A1LMNATLR8 | |
| SCHEMBL9555 | 0.77 | NOTUM (1.00) | NOTUMKDM4EALDH1A1LMNATLR8 | |
| SCHEMBL1500580 | 0.76 | NOTUM (0.60) | NOTUMKDM4EALDH1A1LMNATLR8 | |
| SCHEMBL2670934 | 0.76 | NOTUM (0.65) | NOTUMKDM4EALDH1A1LMNATLR8 | |
| SCHEMBL12254344 | 0.75 | NOTUM (1.00) | NOTUMKDM4EALDH1A1LMNATLR8 | |
| SCHEMBL3537328 | 0.74 | NOTUM (1.00) | NOTUMKDM4EALDH1A1LMNATLR8 | |
| SCHEMBL14814390 | 0.74 | NOTUM (1.00) | NOTUMKDM4EALDH1A1LMNATLR8 | |
| SCHEMBL3685411 | 0.74 | NOTUM (0.64) | NOTUMKDM4EALDH1A1LMNATLR8 | |
| SCHEMBL19356867 | 0.74 | NOTUM (0.64) | NOTUMKDM4EALDH1A1LMNATLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2955173-B1 | 1,2-BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2017-10-04 | — | — | EP | claimed |
| US-9603834-B2 | 1,2- bis-sulfonamide derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-03-28 | — | — | US | claimed |
| US-20160228407-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2016-08-11 | — | — | US | claimed |
| EP-2955173-A1 | NOVEL 1,2-BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2015-12-16 | — | — | EP | claimed |
| EP-2651901-B1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2015-05-27 | — | — | EP | claimed |
| US-20120157444-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | claimed |
| EP-0595164-B1 | 4-heterocyclephenyl substituted dihydropyridines | BAYER AG (DE) | 1996-12-27 | — | — | EP | claimed |
| EP-0595164-A1 | 4-heterocyclephenyl substituted dihydropyridines | BAYER AG (DE) | 1994-05-04 | — | — | EP | claimed |
| EP-0034276-B1 | PHENYLPIPERAZINE DERIVATIVES OF 1,3,4-OXADIAZOLYL PHENOLS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1983-11-09 | — | — | EP | claimed |
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | 4SC AG (DE) | 2023-06-29 | — | — | US | disclosed |
| EP-3212637-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LTD (GB) | 2021-06-02 | — | — | EP | disclosed |
| US-20210145799-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2021-05-20 | — | — | US | disclosed |
| US-20210113528-A1 | Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy | 4SC AG (DE) | 2021-04-22 | — | — | US | disclosed |
| EP-3781557-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2021-02-24 | — | — | EP | disclosed |
| WO-2006040182-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-04-20 | — | — | WO | disclosed |
| US-20050234125-A1 | Alpha-sulfonylamino-acetonitriles | SYNGENTA CROP PROTECTION AG (CH) | 2005-10-20 | — | — | US | disclosed |
| EP-1513802-A1 | ALPHA-SULFONYLAMINO-ACETONITRILES | Syngenta Participations AG (CH) | 2005-03-16 | — | — | EP | disclosed |
| WO-2005021490-A2 | N-SULFONYL-α-AMINO-ACID DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2005-03-10 | — | — | WO | disclosed |
| WO-2004000797-A1 | ALPHA-SULFONYLAMINO-ACETONITRILES | SYNGENTA PARTICIPATIONS AG (CH) | 2003-12-31 | — | — | WO | disclosed |
| US-4353904-A | TREATMENT OF HYPERTONIA | BASF AKTIENGESELLSCHAFT (DE) | 1982-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228407-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CX3CR1 | NOTUM 4390/4885KDM4E 4794/4885ALDH1A1 2379/4885 |
| US-20210145799-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | HDAC8, TLR8, TLR7 | NOTUM 3209/4885KDM4E 319/4885ALDH1A1 1191/4885 |
| US-20210113528-A1 | Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy | HDAC7, HDAC1, HDAC11 | NOTUM 4712/4885KDM4E 786/4885ALDH1A1 384/4885 |
| US-20050234125-A1 | Alpha-sulfonylamino-acetonitriles | C3AR1, C1S, C5 | NOTUM 3417/4885KDM4E 4400/4885ALDH1A1 3512/4885 |
| US-20120157444-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CX3CR1 | NOTUM 4390/4885KDM4E 4794/4885ALDH1A1 2379/4885 |
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | HDAC1, HDAC3, HDAC11 | NOTUM 4142/4885KDM4E 126/4885ALDH1A1 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.